Telix Pharmaceuticals Lim... (TLX)
NASDAQ: TLX
· Real-Time Price · USD
10.28
0.06 (0.59%)
At close: Oct 03, 2025, 3:59 PM
10.07
-2.04%
Pre-market: Oct 06, 2025, 09:25 AM EDT
Telix Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 207.16M | 710.35M | 118.84M | 123.24M | 131.73M | 116.33M | 122.61M | 22.04M | 49.62M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | 4.06M | 6.09M | 10.46M | 12.26M | -5.55M | -5.52M | n/a | n/a | 183K |
Other Long-Term Assets | 53.76M | 74.58M | 287.54M | 586K | 450K | 327K | -3.81M | -3.88M | -58.35M |
Receivables | 129.52M | 158.99M | 97.27M | 64.78M | 64.53M | 39.35M | 16.91M | 19.42M | 365K |
Inventory | 35.23M | 38.14M | 30.8M | 17.31M | 12.6M | 8.48M | 6.53M | 3.45M | 889K |
Other Current Assets | 26.1M | n/a | 8.35M | 7.1M | 10.44M | 6.57M | 3.44M | 1.43M | 19.44M |
Total Current Assets | 398.01M | 918.56M | 255.26M | 224.85M | 219.29M | 173.23M | 149.5M | 47.54M | 70.31M |
Property-Plant & Equipment | 74.18M | 54.32M | 38.26M | 30.49M | 23.09M | 18.84M | 8.49M | 6.33M | 4.58M |
Goodwill & Intangibles | 584.17M | 416.13M | 117.75M | 109.66M | 64.38M | 64.5M | 61.77M | 59.83M | 57.94M |
Total Long-Term Assets | 791.94M | 597.87M | 490.7M | 173.45M | 91.04M | 87.36M | 66.45M | 62.27M | 58.54M |
Total Assets | 1.19B | 1.52B | 745.96M | 398.3M | 310.34M | 260.59M | 215.94M | 109.81M | 128.84M |
Account Payables | 51.69M | 68.7M | 22.31M | 32.84M | 58.69M | 16.81M | 20.16M | 11.88M | 11.14M |
Deferred Revenue | 4.4M | 11.25M | 12.38M | 10.99M | 8.36M | 4.94M | 10.24M | 6.14M | 3.04M |
Short-Term Debt | 12.69M | 18.99M | 1.9M | 964K | 851K | n/a | 555K | 19K | 552K |
Other Current Liabilities | 87.81M | 109.67M | 150.02M | 44.47M | 107.8M | 35.4M | 35.46M | 18.31M | 17.27M |
Total Current Liabilities | 298.58M | 330.91M | 258.37M | 157.41M | 142.63M | 85.56M | 46.55M | 37.98M | 22.29M |
Long-Term Debt | 371.48M | 551.82M | 9.95M | 8.21M | 12.25M | 3.31M | 2.01M | n/a | 1.14M |
Other Long-Term Liabilities | 32.03M | 44.67M | 57.21M | 60.02M | 52.69M | 55.31M | 42.75M | 43.23M | 28.43M |
Total Long-Term Liabilities | 469.43M | 617.31M | 83.61M | 91.98M | 89.21M | 92.88M | 62.74M | 68.19M | 57.57M |
Total Liabilities | 768.01M | 948.22M | 341.98M | 249.39M | 231.84M | 178.44M | 109.29M | 106.17M | 79.86M |
Total Debt | 418.25M | 581.45M | 22.14M | 17.45M | 13.1M | 10.45M | 2.57M | 2.54M | 1.7M |
Book Value | 421.94M | 568.21M | 403.97M | 148.91M | 78.5M | 82.16M | 106.65M | 3.64M | 48.98M |
Book Value Per Share | 1.25 | 1.72 | 1.21 | 0.46 | 0.25 | 0.26 | 0.35 | 0.01 | 0.17 |
Common Stock | n/a | 596.78M | 587.41M | 446.27M | 391.9M | 370.97M | 344.11M | 170.84M | 167.91M |
Retained Earnings | -150.98M | -212.96M | -233.5M | -263.67M | -285.22M | -272.81M | -244.36M | -173.47M | -125.47M |
Comprehensive Income | 99.81M | 184.4M | 50.07M | -33.69M | -30.62M | -18.15M | 5.66M | 4.79M | 5.5M |
Shareholders Equity | 421.94M | 568.21M | 403.97M | 148.91M | 76.06M | 80.01M | 105.41M | 2.16M | 47.93M |
Total Investments | 4.06M | 6.09M | 10.46M | 12.26M | -5.55M | -5.52M | n/a | n/a | 183K |